EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Authors:
Open Access
- 5 October 2022
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
Abstract
Overexpression of the EVI1 (ecotropic viral integration site 1) oncogene has recently been implicated as a prognostic factor in breast cancer (BC), particularly in triple-negative BC (TNBC). In this study we aimed to investigate frequency and clinical relevance of EVI1 expression in newly diagnosed BC treated with neoadjuvant chemotherapy. EVI1 expression was determined by immunohistochemistry using H-score as a cumulative measurement of protein expression in pretherapeutic biopsies of BC patients treated with anthracycline/taxane based neoadjuvant chemotherapy within the GeparTrio trial. EVI1 was analyzed as a continuous variable and dichotomized into low or high based on median expression. Endpoints were pathological complete response (pCR), disease-free survival (DFS) and overall survival (OS). Of the 993 tumors analyzed, 882 had available subtype information: 50.8% were HR + /HER2-, 15% HR + /HER2 + , 9.8% HR-/HER2 + , and 24.5% TNBC. Median EVI1 H-score was 112.16 (range 0.5–291.4). High EVI1 expression was significantly associated with smaller tumor size (p = 0.002) but not with BC subtype. Elevated EVI1 levels were not significantly associated with therapy response and survival in the entire cohort or within BC subtypes. However, TNBC patients with high EVI1 showed a trend towards increased pCR rates compared to low group (37.7% vs 27.5%, p = 0.114; odds ratio 1.60 (95%CI 0.90–2.85, p = 0.110) and numerically better DFS (HR = 0.77 [95%CI 0.48–1.23], log-rank p = 0.271) and OS (HR = 0.76 [95% 0.44–1.31], log-rank p = 0.314) without reaching statistical significance. EVI1 was not associated with response to neoadjuvant therapy or patient survival in the overall cohort. Further analyses are needed to verify our findings especially in the pathological work-up of early-stage HER2-negative BC patients. NCT00544765.Keywords
Funding Information
- Deutsches Krebsforschungszentrum (DKFZ)
This publication has 19 references indexed in Scilit:
- Response-Guided Neoadjuvant Chemotherapy for Breast CancerJournal of Clinical Oncology, 2013
- Deregulated Expression ofEVI1Defines a Poor Prognostic Subset ofMLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative GroupJournal of Clinical Oncology, 2013
- Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22Oncogene, 2010
- EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemiaLeukemia, 2010
- Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous diseaseNature Medicine, 2010
- Evi-1 Is a Critical Regulator for Hematopoietic Stem Cells and Transformed Leukemic CellsCell Stem Cell, 2008
- Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16Leukemia, 2008
- Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio StudyJNCI: Journal of the National Cancer Institute, 2008
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP SystemJournal of Clinical Oncology, 2007
- In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot studyAnnals of Oncology, 2005